Madrigal Pharmaceuticals Strikes Global Licensing Pact with Suzhou Ribo Life Science to Advance siRNA Metabolic Programmes
By Nikita Negi & Lucy Haggerty
Pharma Deals Review: Vol 2026 Issue 2 (Table of Contents)
Published: 26 Feb-2026
DOI: 10.3833/pdr.v2026.i2.3000 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In an effort to strengthen its presence in metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals has signed a licensing agreement with Suzhou Ribo Life Science and its subsidiary, Ribocure Pharmaceuticals, to develop six preclinical siRNA programmes for the treatment of MASH...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS